Previous 10 | Next 10 |
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 PR Newswire HOLON, Israel , April 25, 2024 /PRNewswire/ -- Compugen Ltd...
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 PR Newswire HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pione...
Compugen to Participate in Two Upcoming Investor Conferences PR Newswire HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, tod...
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy PR Newswire HOLON, Israel , March 11, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in ...
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024 PR Newswire HOLON, Israel , March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in compu...
2024-03-05 14:41:06 ET Compugen Ltd. (CGEN) Q4 2023 Earnings Conference Call March 05, 2024, 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto...
2024-03-05 10:02:11 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-05 07:01:32 ET More on Compugen Compugen stock rockets 160% on Gilead development deal Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen Financial information for Compugen Read the full article on Seeking ...
Compugen Reports Fourth Quarter and Full Year 2023 Results PR Newswire Partnership with Gilead on preclinical immuno-oncology program further validates Compugen's computational discovery, research, and development capabilities Catalyst rich 2024 expected with multiple data...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
News, Short Squeeze, Breakout and More Instantly...
Compugen Ltd. Company Name:
CGEN Stock Symbol:
NASDAQ Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 33.8% to $0.0788 on volume of 1,221,538,672 shares Akoustis Technologies Inc. (AKTS) rose 128.8% to $0.3151 on volume of 536,119,838 shares Crown Electrokinetics Corp. (CRKN) rose 3.1% t...
2024-05-21 09:00:12 ET Asthika Goonewardene from Truist Financial issued a price target of $4.00 for CGEN on 2024-05-21 07:48:00. The adjusted price target was set to $4.00. At the time of the announcement, CGEN was trading at $1.74. The overall price target consensus is...